Bellicum Pharmaceuticals, Inc. (BLCM) saw its loss widen to $19.94 million, or $0.74 a share for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $16.85 million, or $0.63 a share.
Revenue during the quarter surged 138.24 percent to $0.08 million from $0.03 million in the previous year period.
Operating loss for the quarter was $19.51 million, compared with an operating loss of $17 million in the previous year period.
"Bellicum had a productive 2016 marked by significant clinical and regulatory progress with our diverse pipeline of controllable cell therapies," said Rick Fair, Bellicum's president and chief executive officer. "On the regulatory front, we clarified our path to approval with BPX-501 and rimiducid in Europe, and made substantial progress in dialogue with the FDA on the design of U.S. registration trials. In the clinic, we initiated two new programs late in 2016 with the first controllable CAR T and TCR candidates that incorporate our novel molecular switch technologies. These accomplishments, and continued enhancement of our technology platform, reinforce our belief that Bellicum is uniquely positioned to deliver important new cell therapies to patients."
Working capital increases marginally
Bellicum Pharmaceuticals, Inc. has recorded an increase in the working capital over the last year. It stood at $90.50 million as at Dec. 31, 2016, up 1.18 percent or $1.05 million from $89.44 million on Dec. 31, 2015. Current ratio was at 6.99 as on Dec. 31, 2016, down from 13.01 on Dec. 31, 2015.
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: editor@irisindia.net
